Related Experiment Video
Updated: Oct 22, 2025

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry
Published on: April 21, 2022
N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
Bingying Du1, Yanbo Zhang2, Meng Liang1
1Department of Neurology, Shanghai Changhai Hospital, The Second Military Medical University, Shanghai, PR China.
Background:
N6 adenosine methylation (m6A) is the most abundant internal RNA modification in eukaryotic cells. Dysregulation of m6A has been associated with the perturbations of cell proliferation and cell death in different diseases. However, the roles of m6A in the neurodegenerative process and cognitive dysfunction are unclear.
Methods:
We systematically investigated the molecular alterations of m6A regulators and their clinical relevance with cognitive dysfunctions using published datasets of Alzheimer's Disease (AD), vascular dementia, and mild cognitive impairment (MCI).
Findings:
The expressions of m6A regulators vary in different tissues and closely correlate with neurodegenerative pathways. We identified co-expressive m6A regulators SNRPG and SNRPD2 as potential biomarkers to predict transformation from MCI to AD. Moreover, we explored correlations between Apolipoprotein E4 and m6A methylations.
Interpretation:
Collectively, these findings suggest that m6A methylations as potential biomarkers and therapeutic targets for cognitive dysfunction.
Funding:
This work was supported by the National Natural Science Foundation of China (81871040) and the Shanghai Health System Talent Training Program (2018BR29).
Related Concept Videos
RNA Editing
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Biosynthesis of Nucleic Acids
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
RNA Stability
Nuclear Export of mRNA

